The clinical transition from acute COVID-19 to symptomatic PASC seems to vary between hospitalized and non-hospitalized patients
Surprisingly, a large number of GLP-1 users are reporting reduced use or total abstinence from substances like alcohol, cannabis, and nicotine
Below is a detailed tirzepatide dosing schedule based on recent studies: Tirzepatide Dose: Initiate at 2.5mg/weekly for the first four weeks, raise to 5mg for weeks 5 to 8, then to 7.5mg for weeks 9 to 12, and 10mg for weeks 13 to 16
Data on the safety and efficacy of such therapies over decades are lacking, creating uncertainty about their role in chronic use, Roberts says
Can GLP-1 medications impact substance use
So if they go on a weight loss strategy to try to lose some of that body fat, then thats fine